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Abbreviations 
 
Aa:  amino acid 
BMZ:  basal membrane zone 
BP:  bullous pemphigoid 
BP180: bullous pemphigoid antigen of 180-kDa / type XVII collagen 
BP230: bullous pemphigoid antigen of 230-kDa 
BSA:  bovine serum albumin 
DEJ:  dermal-epidermal junction 
ELISA: enzyme-linked immuno-assay 
GST:  glutathione-S-transferase 
HRP:  horseradish peroxidase 
IF:  immunofluorescence 
LAD-1: linear IgA disease antigen-1 
NC16A: 16th noncollagenous A domain 
PBS:  phosphate-buffered saline 
PG:  pemphigoid gestationis 
SDS-PAGE:  sodium dodecyl sulfate-polyacrilamide gel electrophoresis 
TBS:  Tris-buffered saline 
TBST:  Tris-buffered saline plus Tween-20 
     
     
Introduction 
 
Organ-specific autoimmune diseases are characterized by T and B cells that 
initiate a reaction against defined self-proteins, which may result in tissue damage. 
In many of these conditions, the epitopes targeted by pathogenic T cells and 
autoantibodies have been extensively characterized in patients and experimental 
animals (Forsthuber et al. 2001; Kuwana et al. 2001; Sekiguchi et al. 2001; 
Tsunoda et al. 2003; Xie et al. 1997; Yang et al. 2002).  
Autoimmune blistering skin diseases represent one group of organ-specific 
autoimmune disorders. They are clinically characterized by blisters and erosions 
and histologically classified as intraepidermal (pemphigus diseases) or 
subepidermal (pemphigoid diseases and epidermolysis bullosa acquisita), 
regarding the level of skin detachment. They are all associated with tissue-bound 
and circulating autoantibodies against structural elements of skin and mucosal 
surfaces.  
Autoantigens recognized by autoantibodies in pemphigus patients are mostly 
components of the desmosomes, structures involved in the intercellular adherence 
among keratinocytes. These structures include desmogleins (Amagai et al. 1991; 
Karpati et al. 1993; Stanley et al. 1982; Wang et al. 1997), desmocollins 
(Hashimoto et al. 1997), plakoglobin (Korman et al. 1989), desmoplakins 
(Hashimoto et al. 1995; Oursler et al. 1992) and plectin (Aho et al. 1999; Proby et 
al. 1999). Non-structural proteins such as acethylcoline receptors have been also 
reported as autoantigens in this group of skin disorders (Nguyen et al. 2000).   
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Figure 1. Autoantigens at the dermal-epidermal junction. The different proteins 
recognized as autoantigens in subepidermal blistering diseases are depicted and 
located on the different layers of the basal membrane zone. BP230 and plectin are 
intracellular hemidesmosomal proteins. BP180 and α6β4-integrin are 
transmembrane proteins of the hemidesmosomes, which project into the lamina 
lucida. BP230 interacts with both transmembrane proteins (Hopkinson and Jones 
2000; Koster et al. 2003). BP180 intracellularly interacts with the β4-unit of α6β4-
integrin (Aho and Uitto 1998). Laminin 5, located in the lamina densa, acts as a 
bridge between α6β4-integrin and type VII collagen (Falk-Marzillier et al. 1998; 
Rousselle et al. 1997), the major component of anchoring fibrils. Anchoring fibrils 
are responsible for the adherence of the basal membrane zone to the dermis 
(dermal collagens). The protein p200 is not yet fully characterized and localizes to 
the lower lamina lucida. In addition, desmosomes, which are structures responsible 
for the epidermal cell-cell adherence are also represented in the figure. In 
intraepidermal blistering diseases (pemphigus), patients present an autoimmune 
response against these desmosomal molecules, e.g. against desmogleins (Dsg).  
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In contrast, the autoimmune response in subepidermal blistering skin diseases is 
directed against multiple molecules of the dermal-epidermal junction (DEJ) (Figure 
1): bullous pemphigoid antigen of 230-kDa (BP230) (Stanley et al. 1981), plectin 
(Laffitte et al. 2001), bullous pemphigoid antigen of 180-kDa (BP180) (Diaz et al. 
1990; Giudice et al. 1992), α6β4-integrin (Bhol et al. 2000; Bhol et al. 2001; Kumari 
et al. 2001; Tyagi et al. 1996), laminin 5 (Domloge-Hultsch et al. 1992; Kirtschig et 
al. 1995; Nousari et al. 1999), type IV collagen (Ghohestani et al. 2000), type VII 
collagen (so-called the epidermolysis bullosa acquisita antigen) (Woodley et al. 
1984) and the not yet characterized p200 protein (Zillikens et al. 1996).  
Pemphigoid gestationis (PG) is a subepidermal autoimmune blistering skin disease 
associated with pregnancy and early postpartum (Shimanovich et al. 2002a; 
Shornick et al. 1983). Disease usually starts during the second half of pregnancy or 
the first weeks of postpartum, with intense pruritus that precedes the onset of skin 
blisters (Shornick 1987). The clinical presentation is polymorphic (papules, 
plaques, targetoid lesions, vesicles and bullae) and blisters are not a constant 
finding (Ogilvie et al. 2000). Initial lesions are typically located on the abdomen and 
later generalize. Mucous membranes are rarely involved (Shimanovich et al. 
2002b). The disease tends to spontaneously improve in the last stages of 
pregnancy, exacerbates after delivery and finally disappears without scarring 
(Shornick 1987). Flares may appear during subsequent pregnancies and hormonal 
contraceptive treatment (Holmes et al. 1983). Cases of PG in association with 
hydatiform mole (Tindall et al. 1981) and choriocarcinoma (do Valle Chiossi et al. 
2000) have also been described.  
An immunopathologic hallmark of PG is the linear deposition of C3 with or without 
IgG at the basement membrane zone (BMZ), as detected by direct 
immunofluorescence (IF) study of perilesional skin (Jordon et al. 1976; Katz et al. 
1976). Circulating IgG autoantibodies can be identified in most PG patients using 
an indirect complement fixation IF technique (Jordon et al. 1976; Katz et al. 1976). 
By immunoelectron microscopy, deposition of immunoreactants is located just 
below the basal keratinocytes, on the upper layer of the lamina lucida 
(Shimanovich et al. 2002a). The autoimmune response in PG is mainly directed 
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against type XVII collagen, also called BP180 (Kelly et al. 1990; Morrison et al. 
1988). Type XVII collagen is a component of hemidesmosomes (Figure 1), 
supramolecular structures that mediate adhesion of basal keratinocytes and certain 
other epithelial cells to the underlying basement membrane (Franzke et al. 2005). 
This glycoprotein consists of an N-terminal intracellular terminus (located in the 
hemidesmosomal plaque), a short transmembrane stretch and a long extracellular, 
rodlike region spanning the entire lamina lucida (Franzke et al. 2005). The different 
components consist of 466, 23 and 1008 amino acids (aa) in length, respectively 
(Franzke et al. 2005). The extracellular C-terminal region contains 15 collagenous 
(COL1-15) and 16 non-collagenous domains (NC1-NC16), some of which are N-
glycosylated (Franzke et al. 2005). Confirmed ligands of type XVII collagen include: 
plectin, BP230 and α6β4-integrin (Hopkinson et al. 1995; Hopkinson et al. 1998; 
Hopkinson and Jones 2000; Koster et al. 2003). Mutations in the human gene of 
type XVII collagen, COL17A1, may lead to rudimentary hemidesmosome formation 
and subsequent dermal-epidermal separation (McGrath et al. 1995). These 
structural alterations are responsible for the clinical hallmarks of junctional 
epidermolysis bullosa, a multi-phenotypic genetic disorder with mucocutaneous 
blistering disease, nail, hair and teeth abnormalities (Franzke et al. 2005).   
In addition to IF studies, immunoblot and enzyme-linked immunosorbent assay 
(ELISA) are useful tools for the diagnosis of PG. Using recombinant forms of type 
XVII collagen/BP180, autoantibodies against this molecule were found in 93 and 
86% of PG patients, as detected by immunoblot and ELISA, respectively (Sitaru et 
al. 2004). The ELISA system may be of special interest in order to guide treatment 
decisions in PG patients, since serum levels of autoantibodies to BP180 seem to 
parallel the clinical disease activity (Sitaru et al. 2004).  
Autoimmunity to type XVII collagen associates not only with PG but also with other 
subepidermal autoimmune blistering skin diseases of the pemphigoid group, 
including bullous pemphigoid (BP) (Diaz et al. 1990; Labib et al. 1986), mucous 
membrane pemphigoid (Balding et al. 1996; Bernard et al. 1992; Bernard et al. 
1990), lichen planus pemphigoides (Davis et al. 1991; Tamada et al. 1995; 
Zillikens et al. 1999a) and linear IgA disease (Zone et al. 1990; Zone et al. 1996; 
 
 
4 
     
Zone et al. 1998; Zillikens et al. 1999b). The pathogenic relevance of 
autoantibodies to type XVII collagen is supported by several lines of evidence: 1) 
the passive transfer of autoantibodies from mothers suffering from PG to the fetus 
induces transient skin blistering in the newborn (Chorzelski et al. 1976; Katz et al. 
1977); 2) serum levels of autoantibodies to type XVII collagen correlate with 
disease activity in patients with BP and PG (Schmidt et al. 2000; Sitaru et al. 
2004); 3) autoantibodies to type XVII collagen from patients with BP recruit 
leucocytes to the DEJ and induce dermal-epidermal separation in cryosections of 
human skin (Sitaru et al. 2002b); 4) rabbit antibodies generated against murine and 
hamster forms of type XVII collagen induce subepidermal blisters when passively 
transferred into neonatal mice or hamsters, respectively (Liu et al. 1993; 
Yamamoto et al. 2002). Studies using these in vitro and in vivo models suggested 
that the epitopes targeted by pathogenic autoantibodies map within the 
extracellular membrane-proximal domain of type XVII collagen, which is 
designated as the 16th non-collagenous domain (NC16A) in humans (Liu et al. 
1993; Yamamoto et al. 2002; Sitaru et al. 2002b; Hofmann et al. 2002). In the 
murine experimental model of autoimmunity to type XVII collagen, a unique linear 
epitope of 9-12 aa is targeted by blister-inducing rabbit antibodies (Liu et al. 1995). 
However, the sequences of human and murine type XVII collagen are not identical 
(Liu et al. 1993). In addition, because of differences between the murine and 
human immune system (Mestas and Hughes 2004), the pathomechanisms of 
blister formation may not be identical in mice compared with patients. The 
pathogenic epitopes in humans have not been yet defined. The characterization of 
these epitopes may have profound implications on the treatment of PG and other 
subepidermal blistering diseases associated with autoantibodies to type XVII 
collagen. In particular, an immunadsorption utilizing short peptides covering the 
pathogenic epitope(s) could be effective in controlling the course of disease. 
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Aim of the study 
 
In the present study, we aimed at defining the epitopes on type XVII collagen that 
are pathogenically relevant for blister formation in patients with PG, and therefore, 
provide the basis for the development of a peptide-specific immunoadsorption 
therapy. We used an in vitro model, in which preparations containing PG 
autoantibodies (serum, total IgG fraction, specific anti-NC16A affinity-purified 
immunoglobulins) are able to induce dermal-epidermal separation in cryosections 
of human skin when co-incubated with leucocytes from healthy donors. First, we 
performed an epitope-mapping study to define which epitopes of type XVII collagen 
are recognized by circulating PG autoantibodies. In a second set of experiments, 
we affinity-purified autoantibodies specific to these epitopes and analyzed their in 
vitro blister-inducing ability. Finally, we addressed the question whether 
preadsorption of PG sera against two synthetic peptides including both major 
antigenic determinants was able to abolish their split-inducing potential.  
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Materials and methods 
 
Patients  
Serum samples were obtained from patients with BP (n=10) and PG (n=23), before 
initiation of treatment, as well as from healthy donors (n=10). All pemphigoid 
patients were characterized by: (i) blistering skin disease; (ii) subepidermal 
cleavage by histopathology; (iii) linear IgG and/or C3 deposition along the DEJ by 
direct IF microscopy; (iv) circulating autoantibodies to the DEJ as revealed by 
indirect IF microscopy; (v) reactivity to type XVII collagen as detected by 
immunoblot analysis and ELISA (Sitaru et al. 2002a; Sitaru et al. 2002b). In 
addition, all PG patients were pregnant or in the early postpartum period. The 
reactivity pattern of those PG patients’ sera that induced dermal-epidermal 
separation in the cryosections of human skin, was analyzed by immunoblotting 
using recombinant forms of BP180 and cell-derived BP180, BP230 and the soluble 
ectodomain of BP180 (LAD-1) (Table I). Antibody reactivity to BP230 was not 
detected in any of our PG patients’ sera.  
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Table I. Reactivity and fine molecular specificity of pemphigoid gestationis 
patients’ autoantibodies   
 BP180 NC16A (aa)a   
Patients 507-520 521-534 507-534 490-562 LAD-1
b
 ELISA
c
 
PG1 + + + + - 111 
PG2 + - + + - 117 
PG3 + - + + - 63 
PG4 + - + + - 112 
PG5 + - + + - 53 
PG6 + - + + - 1387 
PG7 + - + + - 812 
PG8 + - + + - 39 
PG9 + - + + - 102 
PG10 + - + + - 51 
PG11 + - + + + 497 
PG12 + - + + + 92 
PG13 - - - + - 115 
PG14 + - + + - 98 
PG15 + + + + - 115 
PG16 + - + + - 169 
PG17 + - + + - 177 
PG18 + - + + - 233 
PG19 n/d n/d n/d N/d - 96 
 
a Immunoblot reactivity with recombinant fragments covering different amino acid 
sequences of the NC16A domain of type XVII collagen/BP180.  
b Immunoblot reactivity with the soluble ectodomain of type XVII collagen (LAD-1) 
from concentrated conditioned medium of cultured keratinocytes.  
c ELISA using recombinant BP180 NC16A.  
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Preparation of recombinant and cell-derived forms of type XVII collagen  
Glutathione-S-transferase (GST) fusion proteins containing different fragments of 
the NC16A domain of type XVII collagen (Figure 2), including GST-BP180507-520 
(NC16A2), GST-BP180521-534 (NC16A3), GST-BP180490-534 (NC161-3), GST-
BP180507-534 (NC16A2-3), GST-BP180507-562 (NC16A2-5), and GST-BP180490-562 
(NC16A1-5) were expressed in Escherichia coli DH5α (Zillikens et al. 1997) and 
purified by glutathione-agarose immunoaffinity chromatography (Sitaru et al. 2005). 
The soluble shed ectodomain of type XVII collagen (LAD-1) was prepared from 
concentrated conditioned medium of cultured keratinocytes as described 
elsewhere (Zillikens et al. 1999b). The amino-terminus of LAD-1 corresponds to 
Leu524 of the type XVII collagen sequence (Hirako et al. 2003). Cell-derived BP180 
and BP230 were obtained from extracts of human cultured keratinocytes (Sitaru et 
al. 2002b).  
 
Figure 2. Recombinant and synthetic peptides of type XVII collagen (BP180) 
used in this study. The ectodomain of type XVII collagen consists of a series of 
alternating collagenous (C, dark grey) and non-collagenous (NC, light grey) 
domains. The recombinant and synthetic forms of BP180 used in this study are 
depicted to the right. Recombinant peptides (NC16A1-5, NC16A2, NC16A3, 
NC16A2-3, NC16A1-3, NC16A2-5), represented by black bars, cover the whole 
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NC16A domain. Two 16-mere peptides (SP-1, SP-2), which are shown as grey 
bars, were synthesized to include the 2 major antigenic determinants and 
subsequently used for preadsorption experiments. Amino acid residue numbers 
are shown next to the bars. NC1, 1st non-collagenous domain; C15, 15th 
collagenous domain, NC16A, 16th non-collagenous A domain.  
 
Production of synthetic peptides 
Peptides bound to cellulose were automatically synthesized with an ASP 222-Spot 
Roboter (Intavis AG, Cologne, Germany) using the SPOT-synthesis technique 
(Frank 2002). For an initial characterization of epitopes, we synthesized 16-mere 
peptides with an offset of 2 aa covering a stretch of type XVII collagen delimited by 
aa 475 to 677. For a subsequent fine analysis of the epitopes, 16-mere peptides 
were synthesized with an offset of 1 aa residue covering a shorter sequence of 
type XVII collagen spanning aa 491 to 540.  Two peptides SP-1 (aa 499-514) and 
SP-2 (aa 510-525) were synthesized and used for ELISA and preadsorption 
experiments (Figure 2). 
 
Immunofluorescence (IF) microscopy, immunoblotting and ELISA  
IF microscopy analyses followed standard protocols (Sitaru et al. 2002b). The 
complement-fixation test was performed as described (Sitaru et al. 2004; Sitaru et 
al. 2003). The recombinant proteins were subjected to 15% SDS-PAGE and 
electrophoretically transferred to nitrocellulose (Zillikens et al. 1997). 
Immunoblotting using recombinant and cell-derived proteins followed published 
protocols (Sitaru et al. 2002b; Zillikens et al. 1997). For epitope-mapping studies, 
equimolar amounts of the recombinant fragments were separated by SDS-PAGE 
and analyzed by immunoblotting using patients’ sera (Chimanovitch et al. 1999). 
For a fine analysis of target epitopes, peptide spot-membranes were incubated 
with patients’ sera (diluted 1:250 in TBS, pH 7.2) for 1 hour at room temperature 
and washed with TBST. Bound antibodies were visualized with a HRP-labeled anti-
human IgG antibody (DAKOCytomation, Glostrup, Denmark) using 
diaminobenzidine as chromogenic substrate. ELISA using recombinant BP180 
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NC16A was performed following the manufacturer instructions (MBL Co, Nagoya, 
Japan). For ELISAs using synthetic fragments of type XVII collagen, 96-well plates 
(Nunc, Wiesbaden, Germany) were coated with the SP-1 and SP-2 peptides at a 
concentration of 20 µg/ml and treated with 1% BSA in TBS for 1 hour at room 
temperature to block unspecific binding. Patients’ sera diluted 1:100 in TBS were 
incubated for 1 hour at room temperature with the peptide-coated wells, and bound 
antibodies were detected using a HRP-labeled anti-human IgG antibody and 
3,3´,5,5-tetramethylbenzidine as chromogenic substrate. Each serum was assayed 
in triplicate, at least in two independent experiments. 
 
Complement source for immunofluorescence studies and complement 
inactivation of sera 
1 ml aliquotes of fresh frozen human serum from healthy volunteers were used as 
a source of complement. Complement inactivation of sera was achieved by heating 
at 56ºC for 30 minutes (Gammon et al. 1982).  
 
Affinity purification of total IgG and specific anti-BP180 autoantibodies  
Total IgG fraction was purified from serum using protein G chromatography as 
described (Sitaru et al. 2002a). Recombinant proteins GST-BP180507-520, GST-
BP180490-534, and GST-BP180507-562 were covalently coupled to 4% beaded 
agarose at pH 10 as described (Sitaru et al. 2002a; Sitaru et al. 2002b). Synthetic 
peptides were covalently coupled to CNBr-activated agarose (Sepharose 4B; 
Amersham Biosciences, Uppsala, Sweden) following the manufacturer instructions. 
Between 1.2 and 1.5 ml of each serum sample were incubated with the affinity 
matrices for 15-30 minutes at room temperature. Unbound antibodies were 
recovered by collecting the flow-through fraction and the first wash with 1-3 ml of 
PBS (pH 7.2). Antibodies bound to the affinity matrix were eluted with 0.1 M glycine 
buffer (pH 2.8) and the low pH was buffered with 1.5 M Tris-HCl. To achieve a 
complete preadsorption, this procedure was repeated 3-4 times. Both flow-through 
and eluted fractions were concentrated by ultrafiltration with Ultrafree 15 filters 
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(Millipore, Bradford, MA), under extensive washing with PBS (pH 7.2), to 1 ml and 
0.2 ml, respectively. Reactivity of serum, flow-through, and eluted fractions was 
analysed by IF microscopy, immunoblotting and ELISA.  
 
Isolation of peripheral blood leucocytes 
Peripheral blood leucocytes from healthy volunteers were isolated by 
sedimentation gradient with dextran 500 followed by hypotonic lysis of red blood 
cells in 0.2% NaCl. Cells were harvested, washed twice in RPMI 1640 (Life 
Technologies, Karlsruhe, Germany) and resuspended in the same medium at a 
density of 3x107 cells per ml. Cell suspension was kept on ice and cell viability was 
tested by trypan blue exclusion. Only preparations with a viability greater than 95% 
were used.  
 
Treatment of cryostat sections of normal human skin 
Neonatal human foreskin, obtained from routine circumcision, was washed in cold 
PBS, cut in small pieces and embedded in optimum cutting temperature compound 
(Sakura Finetek Europe B.B., Zoeterwonde, The Netherlands), and stored at –
80ºC. Two to four cryosections of 6-µm thickness were obtained and placed in the 
centre of glass microscope slides (Superfrost Plus microscope slides, Menzel-
Gläser, Braunschweig, Germany). Autoantibody preparations (serum, total IgG 
fractions, elution and flow-through fractions from affinity purification) were diluted 
two-fold in PBS and incubated with the cryosections for 90-120 minutes at 37ºC in 
a humidified air incubator containing 5% CO2. After washing the sections twice in 
PBS, chambers with the skin sections were prepared as described (Sitaru et al. 
2002b) and the leucocyte suspension injected into them. Preparations were 
incubated for 3 hours at 37ºC in the same incubator and finally disassembled, 
washed 3 times in PBS for 10 minutes each, fixed in 10% formalin and stained with 
hematoxylin and eosin.  
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Assessment of the blister-inducing potential of autoantibodies  
Blister-inducing capacity of patients’ autoantibodies was evaluated using an in vitro 
model of autoantibody-induced dermal-epidermal separation (Shimanovich et al. 
2004; Sitaru et al. 2002b). The extent of dermal-epidermal separation was scored 
as follows: + for 0-25%, ++ for 25-50%, +++ for 50-75%, and ++++ for 75-100% 
separation of the DEJ. Each experiment was repeated twice to demonstrate the 
reproducibility of the results.  
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Results 
 
Preadsorption against the NC16A domain of type XVII collagen does not 
block autoantibody-induced dermal-epidermal separation in the majority of 
patients with bullous pemphigoid 
Antibodies from BP patients’ sera (n=10) were purified against a recombinant form 
of the immunodominant NC16A domain of type XVII collagen. Total IgG from the 
flow-through fractions was further purified by protein G column chromatography. 
Specificity of antibodies eluted from NC16A coupled to agarose and of IgG purified 
from the flow-through fractions were analysed by IF microscopy and by 
immunoblotting using recombinant NC16A (Figure 3a). Like the original serum 
(Figure 3b), eluted autoantibodies specific to NC16A from all 10 patients induced 
subepidermal splits in cryosections of human skin (Figure 3d). Interestingly, in 7 of 
10 patients, IgG preparations depleted of reactivity to the NC16A domain of type 
XVII collagen (flow-through fractions) continued to induce dermal-epidermal 
separation (Figure 3c). In the remaining 3 patients, flow-through fractions depleted 
of reactivity to NC16A lost their blister-inducing ability. These results indicate that, 
in the majority of BP patients, not only epitopes within but also outside the 
immunodominant region of type XVII collagen or in other BMZ components are 
targeted by blister-inducing autoantibodies. In contrast to BP, the antigenic 
determinants recognized by autoantibodies in PG are virtually restricted to the 
NC16A domain of type XVII collagen (Lin et al. 1999; Sitaru et al. 2003). Peptides 
covering this immunodominant region are available and suitable for 
immunoadsorption. Therefore, we used PG autoantibodies in order to map the 
pathogenically relevant epitopes in type XVII collagen. 
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Figure 3. Preadsorption against the immunodominant region of type XVII 
collagen does not abolish the blister-inducing potential of autoantibodies in 
a majority of bullous pemphigoid patients. Serum from a bullous pemphigoid 
patient was incubated with a protein cocktail consisting of GST-BP180490-534 and 
GST-BP180507-562 encompassing the entire NC16A domain covalently coupled to 
an agarose-beaded gel. The flow-through fraction was collected and bound 
antibodies eluted with 0.1 M glycine (pH 2,7). a, By immunoblotting using 
recombinant BP180 NC16A, IgG autoantibodies eluted from the column (lane 3) 
reacted, as the original serum (lane 1), with NC16A, whereas the flow-through 
fraction (lane 2) or normal serum (lane 4) showed no reactivity.  Sections of human 
frozen skin were incubated with serum (b), flow-through (c) and eluted (d) fractions. 
All three fractions induced dermal-epidermal separation after addition of human 
normal leucocytes (hematoxylin and eosin, 200x). These results are representative 
for 7 of the 10 bullous pemphigoid sera included in this study. 
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Pemphigoid gestationis autoantibodies induce leucocyte-dependent dermal-
epidermal separation in cryosections of human skin 
Serum samples from PG patients (n=23) and IgG purified from 4 PG patients, as 
well as sera and IgG from patients with BP (n=4) and healthy volunteers (n=10), 
were incubated with cryosections of human skin in the presence of leucocytes 
isolated from the peripheral blood of healthy donors. Sera and IgG from 19 of 23 
PG patients, as well as from all BP patients included, induced leucocyte 
recruitment to the DEJ and subepidermal splits in the skin cryosections (Figure 
4c,e). Incubation of skin sections with serum and IgG from healthy controls did not 
result in leucocyte attachment to the epidermal basement membrane or dermal-
epidermal separation (Figure 4d,f). To address the question whether the addition 
of complement increases the extent of dermal-epidermal separation in this model, 
we incubated cryosections, previously treated with PG sera, with 1) leucocytes and 
fresh serum, 2) leucocytes and complement-inactivated (heated) serum, or 3) with 
leucocytes alone. Interestingly, the addition of complement did not increase the 
extent of dermal-epidermal separation in the cryosections compared with the 
extent observed when complement was heat-inactivated or omitted completely 
(data not shown). Therefore, further experiments did not include fresh serum as a 
source of complement.  
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Preadsorption against the NC16A domain of type XVII collagen blocks the 
split formation induced by autoantibodies from pemphigoid gestationis 
patients 
Autoantibodies from PG patients (n=5) were purified against the entire recombinant 
NC16A domain of type XVII collagen. The reactivity and specifity of autoantibodies 
in the eluted and flow-through fractions were characterized by IF microscopy as 
well as ELISA and immunoblotting using recombinant proteins (Table II). When 
incubated with the cryosections, eluted autoantibodies specific to the NC16A 
domain of type XVII collagen from all PG patients induced subepidermal splits 
(Figure 4g), whereas serum fractions depleted of reactivity to this domain lost their 
blister-inducing ability (Figure 4h).  
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Table II. Characterization of patients’ serum fractions affinity-purified against 
recombinant fragments of type XVII collagen  
 
BP180490-562 BP180507-520  
Patients 
 
Fraction IF
a
 ELISA
b
 DES
c
 IF
a
 ELISA
b
 DES
c
 
Serum 1/40 111 + 1/40 111 ++++ 
Eluted fraction 1/80 234 ++ 1/20 84 ++ 
PG1 
Flow-through Neg 7 Neg 1/40 33 ++ 
Serum 1/80 117 ++ 1/80 117 ++ 
Eluted fraction >1/320 427 +++ 1/80 154 ++ 
PG2 
Flow-through Neg  1 Neg Neg 29 + 
Serum 1/20 63 + 1/20 63 +++ 
Eluted fraction 1/80 446 ++ 1/10 35 + 
PG3 
Flow-through Neg 0 Neg Neg 15 ++ 
Serum 1/40 112 +++ 1/40 112 +++ 
Eluted fraction n/d 279 ++++ n/d 58 ++++ 
PG4 
Flow-through Neg 16 Neg Neg  52 ++ 
Serum 1/40 53 ++++ 1/40 53 ++++ 
Eluted fraction 1/80 211 ++++ 1/40 81 +++ 
PG5 
Flow-through Neg 1 Neg Neg 15 ++ 
 
Neg, negative; n/d, not done.  
a Linear deposits of IgG on the epidermal side as demonstrated by 
immunofluorescence (IF) microscopy using sections of 1 M NaCl-split normal 
human skin.   
b ELISA using recombinant BP180 NC16A.  
c The fractions were incubated with cryosections of human skin in the presence of 
leucocytes. Dermal-epidermal separation (DES) was assessed as described in the 
Materials and Methods section.  
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Binding of autoantibodies to more than one epitope of type XVII collagen 
results in subepidermal split formation    
To characterize more closely the epitopes targeted by pathogenic autoantibodies in 
PG, patients sera (n=5) were preadsorbed against a 14-amino acid stretch of type 
XVII collagen (aa 507-520; NC16A2) known to bear the main antigenic 
determinant(s) in PG (Chimanovitch et al. 1999; Lin et al. 1999). Reactivity and 
specificity of the eluted and flow-through fractions were analyzed by IF microscopy, 
ELISA using recombinant NC16A and immunoblotting using different recombinant 
fragments of NC16A, and the results are summarized in Table II. In general, 
preadsorption against NC16A2 led to a drastic reduction of reactivity to both the 
DEJ and to the NC16A domain of type XVII collagen as assessed by IF microscopy 
and ELISA, respectively. Interestingly, antibody preparations depleted of reactivity 
to the GST-BP180507-520 (NC16A2) continued to induce subepidermal splits when 
incubated with the cryosections in all PG patients (Table II, Figure 5e). Antibodies 
specific to GST-BP180507-520 from all patients caused dermal-epidermal separation 
(Table II, Figure 5f). These results indicate that blister-inducing autoantibodies in 
PG bind to more than one epitope on type XVII collagen.  
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Figure 5. Blister-inducing autoantibodies in pemphigoid gestationis target 
multiple epitopes of type XVII collagen. Serum from a pemphigoid gestationis 
patient (PG1) was incubated with a recombinant protein covering aa 507-520 
(NC16A2) of the type XVII collagen/BP180 sequence covalently coupled to an 
agarose-beaded gel. The flow-through fraction was collected and bound antibodies 
were eluted with 0.1 M glycine (pH 2,7). a, By immunoblot analysis using 
recombinant fragments of type XVII collagen, serum autoantibodies reacted with 
different epitopes localized within aa 490-562 of type XVII collagen. b, The flow-
through fraction (preadsorbed serum) showed no reactivity to BP180507-520, but still 
reacted with BP180521-534. c, Conversely, eluted antibodies showed specificity to 
BP180507-520 and did not react with BP180521-534. When incubated with the 
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cryosections in the presence of leucocytes, as the original serum did (d), both the 
flow-through fraction (e) depleted of reactivity to BP180507-520 and eluted antibodies 
(f) specific for this BP180 fragment induced dermal-epidermal separation.  
 
Pemphigoid gestationis autoantibodies recognize two major epitopes within 
the NC16A domain of type XVII collagen 
We used synthetic peptides in order to map more precisely the epitopes 
recognized by PG autoantibodies. Overlapping peptides covering the NC16A 
domain were synthesized with an offset of 1 aa. Reactivity of PG sera (n=12) with 
these synthetic fragments was determined by dot-blot analysis. The results of 
these experiments are exemplified and summarized in Figure 6. PG patients’ 
autoantibodies bound to 2 distinct epitopes on type XVII collagen (Figure 6a,b). 
The binding sites of PG autoantibodies are delimited by aa residues 500 – 514 and 
511 – 523 of type XVII collagen (Figure 6c).  
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Figure 6. Autoantibodies from pemphigoid gestationis patients bind to 2 
distinct epitopes on type XVII collagen. An array of consecutive 16-aa 
fragments covering aa 491-540 of type XVII collagen sequence were synthesized 
with an offset of 1 aa on cellulose membranes. (A) The membrane was incubated 
with patient’s serum (PG3) and subsequently with a HRP-labeled anti-human IgG 
antibody. The reaction was developed using tetramethylbenzidine. PG 
autoantibodies bound to synthetic peptides (boxes) covering aa residues 495-516 
and 507-527. (B) Schematic representation of the peptides recognized by patients’ 
autoantibodies. The common sequence of these peptides is shown in boxes. (C) 
Summary of the epitopes recognized by epitope-mapping analyses of PG sera 
using overlapping synthetic peptides. The sequences of type XVII collagen 
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corresponding to the synthetic peptides used for preadsorption experiments are 
represented as black bars.  
 
Preadsorption against two synthetic peptides including the two major 
epitopes abolishes dermal-epidermal separation induced by pemphigoid 
gestationis autoantibodies 
Serum samples from PG patients (n=9) were preadsorbed against synthetic 
peptides containing the newly defined antigenic epitopes of type XVII collagen. The 
preadsorption was complete as revealed by ELISA using the synthetic peptides 
(data not shown). Reactivity and specificity of the eluted and flow-through fractions 
were analyzed by IF microscopy and ELISA using recombinant NC16A and are 
summarized in Table III. In 8 of 9 patients, in contrast to the original sera and 
eluted fractions, flow-through fractions contained no autoantibodies to the BMZ, 
including no complement-fixing autoantibodies, as assessed by IF microscopy 
(Table III). The levels of autoantibodies detected by ELISA using recombinant 
NC16A generally reflected the results by IF microscopy (Table III). Both original 
sera and eluted antibodies induced dermal-epidermal separation when incubated 
with cryosections of human skin (Table III; Figure 7a,c), whereas preadsorbed 
fractions of all but one PG serum lost their split-inducing ability (Table III; Figure 
7b).  
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Table III. Characterization of patients’ serum fractions immunoaffinity-
purified against two synthetic peptides of type XVII collagen
a
  
 
Patients Fraction IFb ELISAc DESd 
Serum + 116 +++ 
Eluted fraction + 257 ++++ 
1 
Flow-through + 77 ++ 
Serum + 79 + 
Eluted fraction + 69 + 
2 
Flow-through Neg 4 Neg 
Serum + 49 +++ 
Eluted fraction + 54 ++ 
5 
Flow-through Neg 14 Neg 
Serum + 46 ++ 
Eluted fraction + 86 ++ 
8 
Flow-through Neg 5 Neg 
Serum + 105 +++ 
Eluted fraction + 269 ++ 
11 
Flow-through Neg 30 Neg 
Serum +/- 61 +/- 
Eluted fraction +/- 36 + 
14 
Flow-through Neg 12 Neg 
Serum + 71 + 
Eluted fraction + 143 ++ 
15 
Flow-through Neg 11 Neg 
Serum + 99 + 
Eluted fraction + 123 ++ 
16 
Flow-through Neg 38 Neg 
Serum + 114 + 
Eluted fraction +/- 134 ++ 
17 
Flow-through Neg 1 Neg 
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Neg, negative.  
a  Patients’ sera were incubated with synthetic peptides covering aa 499-514 and 
aa 510-525 of type XVII collagen, covalently coupled to an agarose-beaded gel. 
The flow-through fraction was collected and bound antibodies eluted with 0.1 M 
glycine (pH 2,7).  
b Evidence of C3 linear deposits on the epidermal side of 1 M NaCl-split normal 
human skin as demonstrated by immunofluorescence (IF) microscopy, when 
incubating antibody preparations (serum, eluted and flow-through fractions) and a 
complement source, as described in the Materials and Methods section.  
c ELISA using recombinant BP180 NC16A.  
d The fractions were incubated with cryosections of human normal skin in the 
presence of leucocytes. Dermal-epidermal separation (DES) was assessed as 
described in the Materials and Methods section.  
 
 
 
 
 
 
Figure 7. Preadsorption against synthetic peptides covering dominant B cell 
epitopes in pemphigoid gestationis abolishes blister-inducing ability. Serum 
from a pemphigoid gestationis patient was incubated with two synthetic peptides 
covering both epitopes (aa 500-514 and 511-523) of the type XVII collagen 
sequence, previously immobilized in an agarose-beaded gel. The flow-through 
fraction was collected and bound antibodies were eluted with 0.1 M glycine (pH 
2,7). In contrast to the original serum (a), the flow-through fraction (b), depleted of 
reactivity to the epitopes mentioned above, lost its blister-inducing ability. (c) Eluted 
antibodies induced subepidermal separation in cryosections of normal human skin.  
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Discussion 
 
Previous studies suggested that epitopes targeted by blister-inducing 
autoantibodies in pemphigoid diseases localize within the NC16A domain of type 
XVII collagen (Hofmann et al. 2002; Liu et al. 1993; Sitaru et al. 2002b; Yamamoto 
et al. 2002). In the murine experimental model of autoimmunity to type XVII 
collagen, blister-inducing antibodies bound to a single epitope within the 
extracellular membrane-proximal non-collagenous domain of type XVII collagen 
(Liu et al. 1993). In the present study, we show that pathogenic patients’ 
autoantibodies target multiple epitopes on type XVII collagen. Specifically, 2 
pathogenically relevant epitopes are located within the NC16A domain of type XVII 
collagen in PG patients, while blister-inducing autoantibodies in a majority of BP 
patients also target epitopes outside this immunodominant domain.  
In a first set of experiments, we aimed at mapping the epitopes targeted by blister-
inducing autoantibodies in BP patients. Based on previous epitope-mapping data 
(Giudice et al. 1993; Matsumura et al. 1996; Zillikens et al. 1997) and on the initial 
functional data using the cryosection model (Sitaru et al. 2002b),  we hypothesized 
that pathogenically relevant epitopes localize within the NC16A immunodominant 
region of type XVII collagen. Interestingly, preadsorption of BP sera against a 
recombinant form of the entire NC16A region abolished the blister-inducing 
capacity in only about 1/3 of the patients. These data indicate that autoantibodies 
also targeting epitopes outside the immunodominant NC16A domain induce 
dermal-epidermal separation. Overlapping recombinant fragments covering the full-
length of type XVII collagen, which are water-soluble and could be purified in 
sufficient amounts to be used for preadsorption experiments, are currently not 
available. Therefore, a systematic functional characterization of the epitopes 
recognized by blister-inducing autoantibodies in BP was not feasible. In contrast to 
BP, the autoimmune response in PG patients seems to be largely restricted to the 
N-terminal portion of the extracellular domain of type XVII collagen (Lin et al. 1999; 
Sitaru et al. 2003). Different recombinant fragments of this portion of the NC16A 
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domain were available and could be used for preadsorption studies (Zillikens et al. 
1997). These reasons brought us to use sera from PG patients to characterize the 
pathogenic epitopes on type XVII collagen. As it was already described in BP 
(Sitaru et al. 2002b), PG autoantibodies induced dermal-epidermal separation 
when incubated with skin cryosections in the presence of leucocytes. However, in 
contrast to BP autoantibodies, preadsorption against a recombinant form of the 
entire NC16A domain of type XVII collagen successfully abolished the blister-
inducing capacity of autoantibodies in all PG patients.  
Previous epitope-mapping studies using recombinant forms of type XVII collagen 
revealed that autoantibodies from a majority of PG patients exclusively bind to a 
sequence corresponding to aa residues 507-520 (NC16A2) (Chimanovitch et al. 
1999; Lin et al. 1999). Bearing this in mind, further experiments addressed the 
question whether preadsorption against this stretch of type XVII collagen abolishes 
the blister-inducing potential of PG autoantibodies. Interestingly, however, in all PG 
patients, both eluted anti-NC16A2 autoantibodies and serum fractions depleted of 
reactivity to this peptide induced in vitro dermal-epidermal separation. These 
results strongly suggested that blister-inducing autoantibodies recognize multiple 
epitopes within the NC16A domain of type XVII collagen.  
To further characterize the pathogenically relevant targets of PG autoantibodies, 
we generated overlapping synthetic peptides covering the N-terminal sequence of 
the extracellular domain of type XVII collagen. Dot-blot analysis using these 
peptides clearly demonstrated that PG autoantibodies react with 2 distinct 
epitopes. Indeed, preadsorption against these 2 peptides, each containing 1 of the 
2 newly defined epitopes, drastically reduced the reactivity of PG sera as 
measured by IF microscopy, immunoblotting and ELISA. Most importantly, serum 
fractions devoid of reactivity to the newly characterized epitopes lost their split-
inducing potential. The location of these newly defined epitopes explains why our 
first preadsorption attempt against a recombinant fragment corresponding to aa 
residues 507-520 of type XVII collagen (NC16A2) did not abolish the pathogenic 
potential of autoantibodies in PG patients.  
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In the murine model of autoimmunity to type XVII collagen, pathogenic rabbit 
antibodies were shown to bind a unique epitope of 9-12 aa in length located within 
the N-terminal juxtamembranal extracellular region of type XVII collagen (Liu et al. 
1995). This region corresponds in humans to the immunodominant NC16A domain. 
Taken together, these previous data and our present results indicate that the 
NC16A region is a hot spot for pathogenically relevant epitopes in PG and in a 
subgroup of patients with BP.  
Our experiments demonstrate that blister-inducing autoantibodies bind to 2 
epitopes of type XVII collagen in PG.  In addition, our results show that the 
autoclavable synthetic peptides generated for this study are suitable for 
preadsorbing pathogenic autoantibodies. Antigen-specific immunoadsorption using 
short synthetic peptides has been devised and/or applied in other autoantibody-
mediated diseases, including myasthenia gravis and dilated cardiomyopathy 
(Psaridi-Linardaki et al. 2005; Ronspeck et al. 2003; Wallukat et al. 2002). In 
patients with dilated cardiomyopathy, immunoadsorption using peptides that mimic 
the autoantibody-binding epitopes of the β1-adrenergic receptor significantly 
lowered the levels of pathogenic antibodies (Jahns et al. 2004) and improved 
cardiac function (Wallukat et al. 2002). Since clinical improvement parallels the 
reduction of the levels of autoantibodies to type XVII collagen in PG patients 
(Sitaru et al. 2004), an antigen-specific immunoadsorption using these synthetic 
peptides is feasible. With regard to BP, further studies defining the pathogenically 
relevant epitopes are needed; these epitopes could be then used to preadsorb the 
blister-inducing potential of BP autoantibodies and to finally develop an antigen-
specific immunoadsorption.  
 
 
29 
     
Conclusion 
 
This study demonstrates that autoantibodies of PG patients inducing in vitro 
dermal-epidermal separation bind to two main epitopes on type XVII collagen. 
Preadsorption experiments with two immobilized synthetic peptides including both 
major determinants successfully abolished this pathogenic potential. Our findings 
provide the rationale to develop an antigen-specific peptide-based 
immunoadsorber for the treatment of PG.  
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Summary 
 
Pemphigoid gestationis (PG) and bullous pemphigoid (BP) are subepidermal 
autoimmune blistering diseases characterized by self-reactive T and B cells 
specific for the transmembrane hemidesmosomal protein type XVII 
collagen/BP180. Major T and B cell epitopes are located within the 
immunodominant 16th non-collagenous domain A (NC16A) of type XVII collagen. It 
has been suggested that pathogenically relevant autoantibodies also bind to this 
immunodominant region.  
The aim of this study was to map the epitopes targeted by blister-inducing human 
autoantibodies. For this purpose, we used an in vitro model of autoantibody-
induced leucocyte-dependent dermal-epidermal separation. In contrast to the 
majority of patients with BP (7 of 10), preadsorption against a recombinant form of 
the NC16A region abolished the blister-inducing potential of autoantibodies from all 
PG patients tested (n=5). Using overlapping synthetic peptides, we demonstrate 
that PG autoantibodies bind to 2 defined epitopes within the NC16A region (aa 
500-514 and aa 511-523). Preadsorption using an affinity matrix containing these 
two epitopes completely abolished dermal-epidermal separation induced by PG 
autoantibodies (in 8 of 9 patients). These findings provide new insights into the 
pathogenesis of pemphigoid diseases and should prove helpful for the 
development of an antigen-specific immunoadsorption therapy in PG.  
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Zusammenfassung 
 
Pemphigoid gestationis (PG) und bullöses Pemphigoid (BP) sind subepidermal 
Blasen bildende Autoimmundermatosen, die durch autoreaktive T- und B-Zellen 
gegen das hemidesmosomale Transmembranprotein Kollagen Typ XVII / BP180 
gekennzeichnet sind. Die Haupt T- und B-Zell Epitope liegen in der 
immundominanten, nicht-kollagenösen 16. Domäne A (NC16A) des Kollagen Typ 
XVII. Man ging davon aus, dass auch die pathogenen Autoantikörper gegen diese 
immundominante Region gerichtet sind. Das Ziel dieser Studie war es, die 
pathogenetisch relevanten Epitope beim PG zu kartieren. Hierfür wurde ein in vitro-
Modell eingesetzt, in dem Autoantikörper Leukozyten-abhängig eine dermo-
epidermale Spaltbildung induzieren. Im Gegensatz zu einem Großteil der Patienten 
mit BP (7 von 10) führte die Präadsorption gegen eine rekombinante Form der 
NC16A-Region zum Verlust des Blasen induzierenden Potentials aller 
untersuchten PG-Seren (n=5). Mithilfe überlappender synthetischer Peptide 
konnten wir zeigen, dass die Autoantikörper im Serum von PG Patienten an zwei 
definierte Epitope innerhalb der NC16A-Region (aa 500-514 und aa 511-523) 
binden. Die Präadsorption gegen eine Affinitätsmatrix, an die diese 2 Epitope 
gebunden waren, führte zum Verlust der dermo-epidermalen Spaltbildung durch 
PG-Autoantikörper (in 8 von 9 Patienten). Diese Ergebnisse geben weitere 
Einblicke in die Pathogenese der Pemphigoid-Erkrankungen und dürften zur 
Entwicklung Antigen-spezifischer Immunadsorptionstherapien des PG beitragen.  
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